Expression of surface activation markers (CD23, CD25, CD69, and HLA-DR) on eosinophils from unaffected family members (NLs) and patients with FE, HES, or parasitic infections (PARAs)
Patient group . | GM % CD23 (range) . | GM % CD25 (range) . | GM % CD40 (range) . | GM % CD69 (range) . | GM % HLA-DR (range) . |
|---|---|---|---|---|---|
| HES, n = 7 | 1.28 (0.4-1.8) | 4.34 (1.1-22.5) | 0.66 (0.4-1.2) | 5.64 (1.3-18.5) | 3.91 (1.9-33.7) |
| FE, n = 14 | 1.87 (0.6-9.8) | 0.66* (0.2-1.2) | 0.72 (0.3-1.3) | 2.88† (0.3-9.1) | 6.37‡ (1.3-38.2) |
| NL, n = 14 | 2.52 (0.3-10.3) | 0.12 (0.001-1.1) | 0.43 (0.001-2.5) | 0.69 (0.3-1.7) | 2.96 (0.9-15.8) |
| PARA, n = 9 | 1.15 (0.3-5.2) | 0.62 (0.001-6) | 0.48 (0.1-0.9) | 3.02 (0.2-13.6) | 6.05 (1.1-41.6) |
Patient group . | GM % CD23 (range) . | GM % CD25 (range) . | GM % CD40 (range) . | GM % CD69 (range) . | GM % HLA-DR (range) . |
|---|---|---|---|---|---|
| HES, n = 7 | 1.28 (0.4-1.8) | 4.34 (1.1-22.5) | 0.66 (0.4-1.2) | 5.64 (1.3-18.5) | 3.91 (1.9-33.7) |
| FE, n = 14 | 1.87 (0.6-9.8) | 0.66* (0.2-1.2) | 0.72 (0.3-1.3) | 2.88† (0.3-9.1) | 6.37‡ (1.3-38.2) |
| NL, n = 14 | 2.52 (0.3-10.3) | 0.12 (0.001-1.1) | 0.43 (0.001-2.5) | 0.69 (0.3-1.7) | 2.96 (0.9-15.8) |
| PARA, n = 9 | 1.15 (0.3-5.2) | 0.62 (0.001-6) | 0.48 (0.1-0.9) | 3.02 (0.2-13.6) | 6.05 (1.1-41.6) |